AMSTERDAM - The journey for JAK1 tyrosine kinase inhibitor filgotinib has been a bumpy one, advancing among three partners in a dozen years, to find its current place in phase III development for rheumatoid arthritis (RA), Crohn's disease and other autoimmune indications.